Liver Diseases
Welcome,         Profile    Billing    Logout  
 307 Companies   474 Products   474 Products   223 Mechanisms of Action   25 Trials   4911 News 


«12...1617181920212223242526...9899»
  • ||||||||||  Trial completion, Enrollment change, Trial primary completion date:  Elevated Circulating FFA and Intrahepatic Lipid Content (clinicaltrials.gov) -  Nov 15, 2015   
    P=N/A,  N=34, Completed, 
    Recruiting --> Completed | N=12 --> 34 | Trial primary completion date: Dec 2013 --> Jun 2013
  • ||||||||||  Trial completion, Trial primary completion date, HEOR:  Quality of Life After Liver Resection (clinicaltrials.gov) -  Nov 15, 2015   
    P=N/A,  N=198, Completed, 
    Recruiting --> Completed | N=12 --> 34 | Trial primary completion date: Dec 2013 --> Jun 2013 Active, not recruiting --> Completed | Trial primary completion date: Jan 2013 --> Jan 2014
  • ||||||||||  Biomarker, Trial completion, Trial primary completion date:  Alcohol Biomarkers in Post-Liver Transplant Patients (clinicaltrials.gov) -  Nov 10, 2015   
    P=N/A,  N=214, Completed, 
    Trial primary completion date: Oct 2015 --> Oct 2016 Active, not recruiting --> Completed | Trial primary completion date: Jun 2016 --> Oct 2015
  • ||||||||||  Enrollment closed:  Study for Consolidation Period of Chronic Hepatitis B (clinicaltrials.gov) -  Nov 9, 2015   
    P=N/A,  N=136, Active, not recruiting, 
    Trial primary completion date: Aug 2015 --> Nov 2015 Recruiting --> Active, not recruiting
  • ||||||||||  Trial completion, Enrollment change, Trial primary completion date:  New Treatment Response in People With and Without Cirrhosis From Chronic Hepatitis C (clinicaltrials.gov) -  Nov 9, 2015   
    P2,  N=37, Completed, 
    N=160 --> 45 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2015 --> Jan 2015; The trial was terminated due to change in new standard of therapy during the study period. Recruiting --> Completed | N=70 --> 37 | Trial primary completion date: Apr 2016 --> Nov 2015
  • ||||||||||  furaprevir (TG-2349) / TaiGen
    Enrollment open, Trial initiation date, Combination therapy:  Evaluate the Efficacy and Safety of TG-2349 in Subjects With Hepatitis C Infection (clinicaltrials.gov) -  Nov 5, 2015   
    P2,  N=48, Recruiting, 
    Trial primary completion date: Jul 2015 --> Dec 2016 Not yet recruiting --> Recruiting | Initiation date: Jan 2015 --> May 2015
  • ||||||||||  emricasan (IDN 6556) / Histogen, Amerimmune
    Trial primary completion date:  A Study of IDN-6556 in Subjects With Liver Cirrhosis (clinicaltrials.gov) -  Nov 3, 2015   
    P2,  N=80, Active, not recruiting, 
    Enrolling by invitation --> Active, not recruiting Trial primary completion date: Sep 2015 --> Jan 2016
  • ||||||||||  Trial completion:  Sarcopenia and Cirrhosis (clinicaltrials.gov) -  Oct 30, 2015   
    P=N/A,  N=17, Completed, 
    Initiation date: Oct 2013 --> Jun 2013 Recruiting --> Completed
  • ||||||||||  albumin-bound paclitaxel / Generic mfg.
    Trial primary completion date, Metastases:  Hepatic Arterial Infusion (HAI) of Abraxane (clinicaltrials.gov) -  Oct 29, 2015   
    P1,  N=56, Active, not recruiting, 
    Recruiting --> Completed Trial primary completion date: Jun 2016 --> Jun 2017
  • ||||||||||  triptorelin / Generic mfg.
    Trial completion, Enrollment change:  MRI Substudy; Metabolic Changes Due to Iatrogenic Hypogonadism (clinicaltrials.gov) -  Oct 29, 2015   
    P4,  N=31, Completed, 
    Recruiting --> Completed Active, not recruiting --> Completed | N=20 --> 31
  • ||||||||||  Nplate (romiplostim) / Amgen, Kyowa Kirin
    Trial primary completion date:  Romiplostim in Treating Hepatitis C-Infected Patients With Thrombocytopenia (clinicaltrials.gov) -  Oct 28, 2015   
    P2,  N=36, Suspended, 
    Active, not recruiting --> Completed | N=20 --> 31 Trial primary completion date: Apr 2015 --> Apr 2016
  • ||||||||||  Enrollment change, Trial termination:  A Health Intervention to Prevent Depression Hepatitis C Patients (clinicaltrials.gov) -  Oct 27, 2015   
    P2/3,  N=1, Terminated, 
    Trial primary completion date: Jun 2015 --> Jun 2016 N=50 --> 1 | Recruiting --> Terminated; Lack of eligible patients due to introduction of new drugs for Hepatitis C
  • ||||||||||  Trial primary completion date:  Sarcopenia and Cirrhosis (clinicaltrials.gov) -  Oct 23, 2015   
    P=N/A,  N=20, Recruiting, 
    Active, not recruiting --> Completed Trial primary completion date: Jan 2015 --> Dec 2015
  • ||||||||||  Biomarker, Trial primary completion date:  Nonalcoholic Fatty Liver Disease in Taiwanese Children (clinicaltrials.gov) -  Oct 23, 2015   
    P=N/A,  N=800, Recruiting, 
    Trial primary completion date: Jan 2015 --> Dec 2015 Trial primary completion date: Dec 2015 --> Dec 2017
  • ||||||||||  sorafenib / Generic mfg.
    Trial primary completion date, Metastases:  Sorafenib in Liver Function Impaired Advanced Hepatocellular Carcinoma (clinicaltrials.gov) -  Oct 22, 2015   
    P2/3,  N=90, Recruiting, 
    Trial primary completion date: May 2015 --> Nov 2014 Trial primary completion date: Jan 2014 --> Jan 2016
  • ||||||||||  lenalidomide / Generic mfg.
    Trial primary completion date, Metastases:  Lenalidomide as Second-line Treatment for Advanced Hepatocellular Carcinoma (clinicaltrials.gov) -  Oct 22, 2015   
    P2,  N=55, Recruiting, 
    Trial primary completion date: Oct 2015 --> Sep 2016 Trial primary completion date: Jul 2015 --> Dec 2015
  • ||||||||||  Inlyta (axitinib) / Pfizer
    Trial primary completion date, Metastases:  Axitinib as Second-line Treatment for Advanced Hepatocellular Carcinoma (clinicaltrials.gov) -  Oct 22, 2015   
    P2,  N=45, Recruiting, 
    Trial primary completion date: Jul 2015 --> Dec 2015 Trial primary completion date: Aug 2015 --> Mar 2016
  • ||||||||||  Giapreza (LJPC-501) / La Jolla Pharma
    Enrollment change, Trial termination:  A Phase 1 Study of LJPC-501 in Patients With Hepatorenal Syndrome (clinicaltrials.gov) -  Oct 22, 2015   
    P1,  N=6, Terminated, 
    Trial primary completion date: Jun 2015 --> Jun 2016 N=15 --> 6 | Recruiting --> Terminated; Corporate decision
  • ||||||||||  Enrollment change, Trial termination, Trial primary completion date:  Safety and Efficacy of the ELAD System (ELAD) to Treat Acute Liver Failure (ALF) (clinicaltrials.gov) -  Oct 22, 2015   
    P2,  N=8, Terminated, 
    Not yet recruiting --> Recruiting | N=53 --> 29 | Trial primary completion date: Apr 2019 --> Dec 2016 N=40 --> 8 | Recruiting --> Terminated | Trial primary completion date: Feb 2016 --> Sep 2015; Due to VTI-208 results, the ELAD clinical plan is being re-evaluated.
  • ||||||||||  Enrollment change, Trial termination, Trial primary completion date:  To Assess Safety/Efficacy of ELAD in Subjects w/ Severe Acute Alcoholic Hepatitis (sAAH) and Lille Score Failure (clinicaltrials.gov) -  Oct 22, 2015   
    P3,  N=18, Terminated, 
    N=40 --> 8 | Recruiting --> Terminated | Trial primary completion date: Feb 2016 --> Sep 2015; Due to VTI-208 results, the ELAD clinical plan is being re-evaluated. N=150 --> 18 | Recruiting --> Terminated | Trial primary completion date: May 2016 --> Oct 2015; Due to results from the VTI-208 study, the ELAD plan is being re-evaluated.
  • ||||||||||  L-ornithine-L-aspartate / Generic mfg.
    Trial completion, Enrollment change, Trial initiation date, Trial primary completion date:  Brain Muscle Axis During Treatment of Hepatic Encephalopathy With L-ornithine L-aspartate (clinicaltrials.gov) -  Oct 22, 2015   
    P4,  N=42, Completed, 
    N=80 --> 26 | Recruiting --> Terminated | Trial primary completion date: Nov 2015 --> Apr 2015; The sponsor decided not to conduct the expansion part of trial (part 2) Not yet recruiting --> Completed | N=34 --> 42 | Initiation date: May 2013 --> Aug 2013 | Trial primary completion date: Oct 2014 --> Jun 2015